, Northwestern University and Northwestern Memorial Hospital, and member of the NCCN Guidelines Panel for Central Nervous System (CNS) Cancers. At the NCCN 2023 Annual Conference, together with L. Burt Nabors, MD, Vice Chair for Research of Neurology and
Search Results
NCCN Guidelines for Central Nervous System Cancers: Updates in the Treatment of Adult Patients With Glioma
Presented by: Craig M. Horbinski and L. Burt Nabors
Head and Neck Cancers, Version 2.2013
David G. Pfister, Kie-Kian Ang, David M. Brizel, Barbara A. Burtness, Paul M. Busse, Jimmy J. Caudell, Anthony J. Cmelak, A. Dimitrios Colevas, Frank Dunphy, David W. Eisele, Jill Gilbert, Maura L. Gillison, Robert I. Haddad, Bruce H. Haughey, Wesley L. Hicks Jr, Ying J. Hitchcock, Merrill S. Kies, William M. Lydiatt, Ellie Maghami, Renato Martins, Thomas McCaffrey, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, Sandeep Samant, David E. Schuller, Jatin P. Shah, Sharon Spencer, Randal S. Weber, Gregory T. Wolf, Frank Worden, Sue S. Yom, Nicole R. McMillian, and Miranda Hughes
: Integrate into professional practice the updates to NCCN Guidelines for Head and Neck Cancers Describe the rational behind the decision-making process for developing the NCCN Guidelines for Head and Neck Cancers NCCN Categories of Evidence and
Modification and Implementation of NCCN Guidelines™ on Hepatobiliary Cancers in the Middle East and North Africa Region
Muhammed Aasim Yusuf, Vinay Kumar Kapoor, Refaat Refaat Kamel, Ather Kazmi, Najam Uddin, Nehal Masood, and Abdulmajeed Al-Abdulkareem
T he 2009 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Hepatobiliary Cancers (to view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org ) addresses 4 main tumor groups
Uterine Sarcoma, Version 1.2016
Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, Kathleen R. Cho, Christina Chu, David Cohn, Marta Ann Crispens, Don S. Dizon, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Suzanne George, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Fidel A. Valea, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone
, participants will be able to: Integrate into professional practice the updates to the NCCN Guidelines for Uterine Sarcoma Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Uterine Sarcoma NCCN
Attitudes Toward and Use of Cancer Management Guidelines in a National Sample of Medical Oncologists and Surgeons
Reshma Jagsi, Grace Huang, Kent Griffith, Brian J. Zikmund-Fisher, Nancy K. Janz, Jennifer J. Griggs, Steven J. Katz, and Sarah T. Hawley
use of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) specifically, given prior work suggesting that these were the most commonly used cancer management guidelines. 5 Respondents were first asked if they knew that NCCN provides
Letter to the Editor: No Evidence to Promote Interim FDG-PET Adapted Therapy in the NCCN Guidelines for Hodgkin Lymphoma
Hugo J.A. Adams and Thomas C. Kwee
Trends in Female Representation on NCCN Guideline Panels
Pranammya Dey, Angela K. Green, Michael Haddadin, Peter B. Bach, and Aaron P. Mitchell
from NCCN Member Institutions. Previous work has suggested that female representation on NCCN Guidelines Panels tends to reflect the underlying proportion of accomplished female researchers working in each tumor type. 2 Throughout academic medicine
Ovarian Cancer, Version 3.2012
Robert J. Morgan, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Mariana Castells, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Russell J. Schilder, Julian Schink, Nelson Teng, Theresa L. Werner, Miranda Hughes, and Mary A. Dwyer
NCCN Guidelines Insights : Ovarian Cancer,Version 3.2012 Version 3.2012 © National Comprehensive Cancer Network, Inc. 2012, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the
Soft Tissue Sarcoma, Version 2.2014
Margaret von Mehren, R. Lor Randall, Robert S. Benjamin, Sarah Boles, Marilyn M. Bui, Ephraim S. Casper, Ernest U. Conrad III, Thomas F. DeLaney, Kristen N. Ganjoo, Suzanne George, Ricardo J. Gonzalez, Martin J. Heslin, John M. Kane III, Joel Mayerson, Sean V. McGarry, Christian Meyer, Richard J. O’Donnell, Alberto S. Pappo, I. Benjamin Paz, John D. Pfeifer, Richard F. Riedel, Scott Schuetze, Karen D. Schupak, Herbert S. Schwartz, Brian A. Van Tine, Jeffrey D. Wayne, Mary Anne Bergman, and Hema Sundar
: Integrate into professional practice the updates to NCCN Guidelines for Soft Tissue Sarcoma Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Soft Tissue Sarcoma NCCN Categories of Evidence and Consensus
Kidney Cancer, Version 2.2014
Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Kanishka Sircar, Brad Somer, Jue Wang, Richard B. Wilder, Mary A. Dwyer, and Rashmi Kumar
to: Integrate into professional practice the updates to NCCN Guidelines for Kidney Cancer Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Kidney Cancer NCCN Categories of Evidence and
